Сунитиниб при нейроэндокринных опухолях поджелудочной железы. Клинический случай

СтатьяМЕД СОВЕТ. 2019; № 19: 114–118. DOI:10.21518/2079-701X-2019-19-114-118

Маркович А.А.^[1]

Кузнецова А.А.^[1]

Дронова Е.Л.^[1]

Емельянова Г.С.^[2]

^[1]Национальный медицинский исследовательский центр имени Н.Н.Блохина Министерства здравоохранения Российской Федерации

^[2]Московский государственный медико-стоматологический университет им. А. И. Евдокимова

нейроэндокринная опухоль

рецепторы соматостатина

сунитиниб

таргетная терапия

ланреотид

Больные

Данных сбор

Железо

Москва

Нейроэндокринные новообразования

Новообразований метастазы

Поджелудочная железа

Рецепторы соматостатина

Сунитиниб

Fjallskog M.L., Lejonklou M.H., Oberg K.E., Eriksson B.K., Janson E.T. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res. 2003;9(4):1469–1473. Available at: https://clincancerres.aacrjournals.org/content/9/4/1469.long.https://clincancerres.aacrjournals.org/content/9/4/1469.long

Kulke M.H., Lenz H.J., Meropol N.J., Posei J., Ryan D.P., Picus J., Bergsland E., Stuart K., Tye L., Huang X., Li J.Z., Baum C.M., Fuchs C.S. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20):3403–3410. doi: 10.1200/JCO.2007.15.9020..
DOI: 10.1200/JCO.2007.15.9020

Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J.S., Hörsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D.R., Blanckmeister C., Chao R., Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513. doi: 10.1056/NEJMoa1003825..
DOI: 10.1056/NEJMoa1003825

Valle J.W., Borbath I., Rosbrook B., Fernandez K., Raymond E. Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. Future Oncology. 2019;15(11):1219-1230. doi: 10.2217/fon-2018-0882..
DOI: 10.2217/fon-2018-0882

Faivre S., Niccoli P., Castellano D., Valle J.W., Hammel P., Raoul J.L., Vinik A., Van Cutsem E., Bang Y.J., Lee S.H., Borbath I., Lombard-Bohas C., Metrakos P., Smith D., Chen J.S., Ruszniewski P., Seitz J.F., Patyna S., Lu D.R., Ishak K.J., Raymond E. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a Phase III randomized study. Ann Oncol. 2016;28(2):339–343. doi: 10.1093/annonc/mdw561..
DOI: 10.1093/annonc/mdw561

Raymond E., Kulke M.H., Qin S., Yu X., Schenker M., Cubillo A., Lou W., Tomasek J., Thiis-Evensen E., Xu J.M., Croitoru A.E., Khasraw M., Sedlackova E., Borbath I., Ruff P., Oberstein P.E., Ito T., Jia L., Hammel P., Shen L., Shrikhande S.V., Shen Y.,

Sufliarsky J., Khan G.N., Morizane C., Galdy S., Khosravan R., Fernandez K.C., Rosbrook B., Fazio N. Efficacy and safety of sunitinib in patients with well-differentiated pancreatic neuroendocrine tumours. Neuroendocrinology. 2018;107(3):237–245. doi: 10.1159/000491999..
DOI: 10.1159/000491999

Rinzivillo M., Fazio N., Pusceddu S., Spallanzani A., Ibrahim T., Campana D., Marconcini R., Partelli S., Badalamenti G., Brizzi M.P., Catena L., Schinzari G., Carnaghi C., Berardi R., Faggiano A., Antonuzzo L., Spada F., Gritti S., Femia D., Gelsomino F., Bongiovanni A., Ricci S., Brighi N., Falconi M., Delle Fave G., Panzuto F. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: a real-world study. Pancreatology. 2018;18(2):198–203. doi: 10.1016/j.pan.2018.01.005..
DOI: 10.1016/j.pan.2018.01.005

Theodoropoulou M., Stalla G.K. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34(3):228–252. doi: 10.1016/j.yfrne.2013.07.005..
DOI: 10.1016/j.yfrne.2013.07.005

Kulaksiz H., Eissele R., Rössler D., Schulz S., Höllt V., Cetin Y., Arnold R.. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50(1):52–60. doi: 10.1136/gut.50.1.52..
DOI: 10.1136/gut.50.1.52

Somvanshi R.K., Kumar U. Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors. Pharmaceuticals (Basel). 2012;5(5):417–446. doi: 10.3390/ph5050417..
DOI: 10.3390/ph5050417

Modlin I.M., Pavel M., Kidd M., Gustafsson B.I. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–188. doi: 10.1111/j.1365-2036.2009.04174.x..
DOI: 10.1111/j.1365-2036.2009.04174.x

Wilson B.J., Harada R., LeDuy L., Hollenberg M.D., Nepveu A. CUX1 transcription factor is a downstream effector of the proteinase-activated receptor 2 (PAR2). J Biol Chem. 2009;284(1):36–45. doi: 10.1074/jbc.M803808200..
DOI: 10.1074/jbc.M803808200

Segal N.H., Saltz L.B. Evolving treatment of advanced colon cancer. Annu Rev Med. 2009;(60):207–219. doi: 10.1146/annurev.med.60.041807.132435..
DOI: 10.1146/annurev.med.60.041807.132435

Yao J.C., Lombard-Bohas C., Baudin E., Kvols L.K., Rougier P., Ruszniewski P., Hoosen S., St Peter J., Haas T., Lebwohl D., Van Cutsem E., Kulke M.H., Hobday T.J., O’Dorisio T.M., Shah M.H., Cadiot G., Luppi G., Posey J.A., Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69–76. doi: 10.1200/JCO.2009.24.2669..
DOI: 10.1200/JCO.2009.24.2669

Bajetta E., Catena L., Pusceddu S., Spada F., Iannacone C., Sarno I., Di Menna G., Dottorini L., Marte A.M. Everolimus in Combination with Octreotide Long-Acting Repeatable in a FirstLine Setting for Patients with Neuroendocrine Tumors: A 5-Year Update. Neuroendocrinology. 2018;106(4):307–311. doi: 10.1159/000479587..
DOI: 10.1159/000479587

Krug S., Mordhorst J.P., Moser F., Theuerkorn K., Ruffert C., Egidi M., Rinke A., Gress T.M., Michl P. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells. PLoS One. 2019;14(6):e0218953. doi: 10.1371/journal.pone.0218953..
DOI: 10.1371/journal.pone.0218953

Durán-Prado M., Saveanu A., Luque R.M., Gahete M.D., Gracia-Navarro F., Jaquet P., Dufour H., Malagón M.M., Culler M.D., Barlier A., Castaño J.P. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab. 2010;95(5):2497-2502. doi: 10.1210/jc.2009-2247..
DOI: 10.1210/jc.2009-2247

Caplin M.E., Pavel M., Ćwikła J.B., Phan A.T., Raderer M., Sedláčková E., Cadiot G., Wolin E.M., Capdevila J., Wall L., Rindi G., Langley A., Martinez S., Gomez-Panzani E., Ruszniewski P. CLARINET Investigators. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191-199. doi: 10.1530/ERC-15-0490.
DOI: 10.1530/ERC-15-0490

Capdevila J., Sevilla I., Alonso V., Antón Aparicio L., Jiménez Fonseca P., Grande E., Reina J.J., Manzano J.L., Alonso Lájara J.D., Barriuso J., Castellano D., Medina J., López C., Segura Á., Carrera S., Crespo G., Fuster J., Munarriz J., García Alfonso P. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015;(15):495. doi: 10.1186/s12885-015-1512-6..
DOI: 10.1186/s12885-015-1512-6

Язык текста: Русский

ISSN: 2079-701X